The most frequent AEs related to famitinib were proteinuria, hand-foot syndrome, fatigue, and hypertension in the present study, which were consistent with those observed in a phase I study [14] and typical AEs of small-molecule VEGF TKIs [10, 11]. This evidence concerns the gene VEGFA and Hypertension.